May 19/04
A pair of studies at UCLA's Jonsson Cancer Center taking laboratory science to the patient bedside found that combining the molecularly targeted therapy Herceptin with a specific chemotherapy combination resulted in significant tumor response rates and longer relapse-free periods in women with an aggressive form of advanced breast cancer... Read the rest of the article at: http://www.medicalnewstoday.com/index.php?newsid=8460 |
All times are GMT -7. The time now is 12:06 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021